arrow
E

Eunice Yuen

Eli Lilly and Company
H指数:21
被引数:1,344

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
CANCER
IF5.1
2025-02-110
PRE
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

一项关于LOXO-338(一种口服选择性Bcl-2抑制剂)在晚期血液系统恶性肿瘤患者中的首次人体I期研究

2025-01-280
PRE
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine
2020-02-0676
OAAI